Oligometastatic breast cancer: back to square one in the era of precision oncology

Edoardo Bruno; Andrea Columpsi; Camilla Cavaliere; Annalisa Piccinetti; Francesco Cavaliere

doi:10.18203/2349-2902.isj20261593

Authors

Edoardo Bruno Department of Plastic, Reconstructive and Aesthetic Surgery, Sapienza University of Rome, Rome, Italy
Andrea Columpsi Department of Plastic, Reconstructive and Aesthetic Surgery, Sapienza University of Rome, Rome, Italy
Camilla Cavaliere Breast Unit, Ospedale Santa Rosa, Viterbo, Italy
Annalisa Piccinetti Breast Unit, Ospedale Santa Rosa, Viterbo, Italy
Francesco Cavaliere Breast Unit, Ospedale Santa Rosa, Viterbo, Italy

DOI:

https://doi.org/10.18203/2349-2902.isj20261593

Keywords:

Oligometastatic breast cancer, Surgery, Precision oncology, Liquid biopsy, ctDNA, Biopsy, Biomarkers

Abstract

Metastatic breast cancer (MBC) has long been considered the paradigm of an incurable systemic disease. Once distant dissemination occurs, therapeutic strategies have traditionally focused on disease control, symptom palliation, and survival prolongation rather than cure. Yet, as systemic therapies become increasingly effective and diagnostic tools more sensitive, the classical distinction between localized and metastatic disease appears progressively less absolute.

References

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8-10.

Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002;132(4):620-6.

Gera R, Chehade HEH, Wazir U, Tayeh S, Kasem A, Mokbel K. Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216,066 patients: a meta-analysis. Sci Rep. 2020;10:2955.

Soran A, Ozmen V, Ozbas S, Hasan K, Mahmut M, Abdullah I, et al. Randomized trial comparing locoregional resection of the primary tumor with no surgery in stage IV breast cancer at presentation: MF07-01 trial. Ann Surg Oncol. 2018;25(11):3141-9.

Badwe R, Hawaldar R, Nair N, Rucha K, Vani P, Shabina S, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomized controlled trial. Lancet Oncol. 2015;16(13):1380-8.

Fitzal F, Bjelic-Radisic V, Knauer M, Günther S, Michael H, Marija B, et al. Impact of breast surgery in primary metastatic breast cancer: outcomes of the randomized phase III ABCSG-28 POSYTIVE trial. Ann Surg. 2019;269(6):1163-9.

Khan SA, Zhao F, Solin LJ, David C, Mark B, Mehra G, et al. Early local therapy for the primary site in patients with de novo stage IV breast cancer: results of a randomized clinical trial (E2108). J Clin Oncol. 2022;40(9):978-87.

Swain SM, Baselga J, Kim SB, Jungsil R, Vladimir S, Mario C, Eva C, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer (CLEOPATRA study). N Engl J Med. 2015;372(8):724-34.

Milano MT, Katz AW, Zhang H, Ann GM, Paul O. Oligometastatic breast cancer treated with stereotactic body radiotherapy: long-term outcomes. Breast Cancer Res Treat. 2012;131(3):601-8.

Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. JAMA. 1994;271(20):1593-7.

Schmid P, Adams S, Rugo HS, Andreas S, Carlos HB, Hiroji I, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108-21.

Coombes RC, Page K, Salari R. Personalized detection of circulating tumor DNA in early-stage breast cancer. Sci Transl Med. 2019;11:eaax7392.